Download Access to Medicine Versus Test Data Exclusivity: by Owais H. Shaikh PDF

By Owais H. Shaikh

This ebook explores the idea that of attempt facts exclusivity defense for prescribed drugs. concentrating on paintings 39(3) of the WTO contract on Trade-Related facets of highbrow estate Rights (TRIPS contract) and appropriate provisions in chosen loose alternate agreements (FTA) and nationwide legislation, it combines normative, historic, comparative and fiscal research of try info exclusivity protection.At the guts of this ebook is the unconventional and unique Index of knowledge Exclusivity and entry (IDEAS), which analyzes the effectiveness of attempt info exclusivity provisions in FTAs and nationwide legislation either at the power of exclusivity in addition to on entry to drugs. principles offers a framework for the overview of present try facts exclusivity safeguard criteria at the foundation in their proximity to Article 39(3) of the journeys contract, the scope of exclusivity and the flexibilities in FTAs, and to that end in nationwide legislation. This ebook goals to expand nationwide and foreign coverage makers’ grab of a number of the nuances of try out info exclusivity safeguard. moreover, it offers useful options with reference to designing a suitable felony approach with a powerful specialize in selling entry to drugs for all.

Show description

Read Online or Download Access to Medicine Versus Test Data Exclusivity: Safeguarding Flexibilities Under International Law PDF

Similar commercial books

International Commercial Litigation: Text, Cases and Materials on Private International Law

This conscientiously based, practice-orientated textbook presents every little thing the legislation scholar must learn about foreign advertisement litigation. The powerful comparative part presents a thought-provoking foreign point of view, whereas while permitting readers to achieve specific insights into litigation in English courts.

Limits of Patentability: Plant Sciences, Stem Cells and Nucleic Acids

SpringerBriefs in Biotech Patents offers well timed stories on highbrow homes (IP) concerns and patent features within the box of biotechnology. during this quantity the bounds of patentability are addressed, a question that's usually raised in terms of biotechnological innovations: the 1st part addresses present matters within the patentability of vegetation produced by means of basically organic tactics together with the talk among farmer’s privilege and patent exhaustion with appreciate to seeds within the US.

Commercial Contracts. A Practical Guide to Deals, Contracts, Agreements and Promises

This ebook goals to give an explanation for the foundations of agreement legislations for the businessman, and to place these rules into their advertisement context. someone desirous about advertisement transactions wishes a minimum of a easy knowing of the rules of agreement legislation - the criminal framework for all advertisement task.

Economic Impacts of Intellectual Property-Conditioned Government Incentives

This ebook presents new insights into the commercial affects, strategic ambitions and criminal buildings of an rising department of presidency incentives conditioned on assembly highbrow property-related specifications. regardless of changing into extra universal lately, such incentives – starting from patent expense subsidies and patent field tax deductions to inventor remuneration schemes – are nonetheless under-researched.

Extra resources for Access to Medicine Versus Test Data Exclusivity: Safeguarding Flexibilities Under International Law

Sample text

Art 3(2) Regulation 726/2005. See Sect. 2 for further discussion. Under patent law, the industrial applicability or utility requirement is present but there too there criteria is not that the pharmaceutical invention should be an advancement over existing products. 20 There may be cases where some novelty and non-obviousness is present in line extensions. In such a case, further patenting for another 20 years could be possible. 21 Fackelmann (2013) at 172–9. 22 This may be seen as similar to the practice of ever-greening of protection of pharmaceutical products.

But is it right to assume that test data would not be produced if not specifically incentivized? Moreover, is it necessary to confer an exclusive right as an incentive to produce such data? 12 In fact in the present case, test data is a public good that is, at best, an intermediate product, necessary for the production of the end product, the pharmaceuticals. This is by virtue of the legal requirement to provide proof for safety and efficacy of the pharmaceutical product. 15 11 Holcombe (1997) at 7 (using the example of television and radio broadcasts).

16 For an overview of alternatives to patent incentives, see generally, Stephen M. Maurer, When Patents Fail: Finding New Drugs for the Developing World in Pharmaceutical Innovation: Incentives, Competition and Cost-Benefit Analysis in International Perspective 108 (Frank A. Salon & Chee-Ruey Hsieh ed. 2007). 17 See notes 47–50 in Chap. 1. 18 To be fair, there is a quasi-novelty requirement for pharmaceutical products containing new chemical entities. The US law grants five years of test data exclusivity protection only to pharmaceutical products that contain a new chemical entity.

Download PDF sample

Rated 4.68 of 5 – based on 30 votes